Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

$3.1 million and $1.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $1.8 million was primarily due to increased costs related to patent prosecution, personnel-related expenses, stock-based compensation expense and consulting for market research, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $8.7 million and $2.0 million for the three months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

Year-To-Date Results
Revenues were $25.8 million and $14.7 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $11.1 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $20.2 million and $30.1 million for the nine months ended September 30, 2013 and 2012, respectively.  The decrease of $10.0 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, for which enrollment of patients was completed in late 2011. 

General and administrative expenses were $7.0 million and $4.5 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $2.5 million was primarily due to increased costs related to patent prosecution, stock-based compensation expense, personnel-related expenses and consulting for market res
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry is ... with a focus on the Chinese situation. Major companies included in the propanol market ... Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides a ...
(Date:7/30/2015)... , July 30, 2015  With over 60,000 customers across the globe, ISN improves ... 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over ... Headquartered in Dallas, TX ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... applications and designed for continuous operation up to 1500 bar. The sanitary design ... efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal ...
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / 20% of ... growth in China , as well as solid contributions from ... Europe / Middle East / ... gains in Germany , Turkey and ... / 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... 16%, net Profit up 17%, - Sound Financial Position, - Proposed Increase in Dividend, , ... EUR millions 2007 ... ... %, ...
... March 24 Stallergenes S.A. and,Solvay Pharmaceuticals Marketing ... signing of an exclusive partnership agreement for the,promotion ... Russia and the Commonwealth of Independent States (CIS). ... 20 million allergy sufferers and a strong demand ...
... 24 Accera, Inc., a biotechnology company delivering breakthrough ... that Thomas Werner, Ph.D. has been elected to its ... managing director and senior vice president of GlaxoSmithKline (GSK) ... until earlier this year. He led the Pharmaceutical Research ...
Cached Biology Technology:STALLERGENES: 2008: Strong Performance 2STALLERGENES: 2008: Strong Performance 3Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 2Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 3Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors 2
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 /PRNewswire/ ... today announced BD & Guidepoint Mentor, a ... access to Guidepoint,s expert network services. ... cutting-edge technologies to improve healthcare delivery and outcomes and, ... each start-up entrepreneur will be able to directly engage ...
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... STATION When Atlantic Richfield Co. was tasked with cleaning ... Dr. Frank Hons, a Texas A&M University professor, got a ... Hons, a soil and crop science professor, spent two years ... impacted by 100 years of copper mining, mineral processing and ...
... world leader in synthetic diamond supermaterials, and academic ... Chemistry and Physics, have demonstrated the key factors ... synthetic diamond. The research shows that boron-doped synthetic ... full strength and durability of its chemical structure. ...
... Technology (Caltech) have been able, for the first time, ... DNA, and to measure the rate at which that ... infection by this type of virusa bacteriophagethe scientists have ... rather than the amount of genetic material within the ...
Cached Biology News:Mining cleanup benefits from Texas A&M expertise 2Mining cleanup benefits from Texas A&M expertise 3Synthetic diamond steps closer to next generation of high performance electrochemical applications 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 3The physics of going viral 2The physics of going viral 3The physics of going viral 4
SHEEP ANTI DEHYDROEPIANDROSTERONE...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure Grade DAPI is greater than or equal to 98% pure by HPLC....
... et.al. (1997) • Contains short ... biochemistry & molecular biology, arranged ... Entries give details of biochemical ... which they are involved and ...
... • This book describes the basic ... preparing samples for protein transfer and ... bioluminescence-enhanced detection systems are also included. ... and characterization of glycoprotein carbohydrate chains ...
Biology Products: